Abstract | OBJECTIVES: METHODS: RESULTS: Anti-CarP positive patients (n=18) were younger (p=0.01) and with a longer disease duration (p=0.05) when compared to anti-CarP negative patients (n=42) at baseline. Considering the entire cohort, a significant reduction of anti-CarP titre after twelve-months of treatment was shown (p<0.01). A significant reduction of Disease Activity Score ( DAS) 28-C-reactive protein (CRP) in the first six months of therapy was found in the subgroup of anti-CarP positive patients in comparison with the negative ones (p=0.003). No significant results were found by dividing the cohort using the positivity to anti-CCP and/or RF. CONCLUSIONS: Earlier onset and a longer disease duration in anti-CarP positive patients might suggest they are specific risk factors for RA in this subgroup of patients. The correlation between the anti-CarP positivity at baseline and the reduction of disease activity during the first six months of treatment with abatacept allowed us to hypothesise that anti-CarP antibodies, but not anti-CCP and/or RF, could be used as a good clinical response predictor.
|
Authors | Rajesh Kumar, Silvia Piantoni, Michele Boldini, Emirena Garrafa, Chiara Bazzani, Micaela Fredi, Roberta Ottaviani, Ilaria Cavazzana, Angela Tincani, Franco Franceschini |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2021 Jan-Feb
Vol. 39
Issue 1
Pg. 91-97
ISSN: 0392-856X [Print] Italy |
PMID | 32359037
(Publication Type: Journal Article)
|
Chemical References |
- Autoantibodies
- Peptides, Cyclic
- Abatacept
- Rheumatoid Factor
|
Topics |
- Abatacept
(therapeutic use)
- Arthritis, Rheumatoid
(diagnosis, drug therapy)
- Autoantibodies
- Humans
- Peptides, Cyclic
- Rheumatoid Factor
|